| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T3 |
0-65 |
Sentence |
denotes |
Seven coronaviruses (CoVs) have been isolated from humans so far. |
| T4 |
66-388 |
Sentence |
denotes |
Among them, three emerging pathogenic CoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and a newly identified CoV (2019-nCoV), once caused or continue to cause severe infections in humans, posing significant threats to global public health. |
| T5 |
389-616 |
Sentence |
denotes |
SARS-CoV infection in humans (with about 10% case fatality rate) was first reported from China in 2002, while MERS-CoV infection in humans (with about 34.4% case fatality rate) was first reported from Saudi Arabia in June 2012. |
| T6 |
617-762 |
Sentence |
denotes |
2019-nCoV was first reported from China in December 2019, and is currently infecting more than 70000 people (with about 2.7% case fatality rate). |
| T7 |
763-930 |
Sentence |
denotes |
Both SARS-CoV and MERS-CoV are zoonotic viruses, using bats as their natural reservoirs, and then transmitting through intermediate hosts, leading to human infections. |
| T8 |
931-1072 |
Sentence |
denotes |
Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. |
| T9 |
1073-1218 |
Sentence |
denotes |
Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. |
| T10 |
1219-1495 |
Sentence |
denotes |
In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. |
| T11 |
1496-1752 |
Sentence |
denotes |
These subunit vaccines are introduced on the basis of full-length spike (S) protein, receptor-binding domain (RBD), non-RBD S protein fragments, and non-S structural proteins, and the potential factors affecting these subunit vaccines are also illustrated. |
| T12 |
1753-1905 |
Sentence |
denotes |
Overall, this review will be helpful for rapid design and development of vaccines against the new 2019-nCoV and any future CoVs with pandemic potential. |
| T13 |
1906-1979 |
Sentence |
denotes |
This review was written for the topic of Antivirals for Emerging Viruses: |
| T14 |
1980-2059 |
Sentence |
denotes |
Vaccines and Therapeutics in the Virology section of Frontiers in Microbiology. |
